Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs MultiMedRx

Kin Meds
Graded #75

Higher grade

vs+15.300000000000004
MultiMedRx
Graded #394

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 57.6/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +29
74
45
Dose & formulationKin Meds +40
93
53
Clinical oversightMultiMedRx +5
74
79
Labs & monitoringEven
53
53
FulfillmentKin Meds +5
72
67
Contract termsKin Meds +6
55
49
Kin Meds · left barMultiMedRx · right bar

The numbers

MetricKin MedsMultiMedRx
WeighScore72.9/10057.6/100
GradeCC
Scorecard rank#75#394
Semaglutide$149/mo (brand Wegovy)Not disclosed
Tirzepatide$149/mo (brand Zepbound)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
MultiMedRx

Graded #394 · C

Strengths

  • Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
  • Two physical addresses listed: Newport Beach, CA and Reno, NV
  • LegitScript seal present
  • Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
  • Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1

Where it loses points

  • No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
  • Monthly GLP-1 pricing isn't published — gated behind the consultation
  • $100 consultation fee adds friction; many peers bundle it into the medication price
  • Per-state availability not listed; only CA and NV offices disclosed
  • Whether compounded GLP-1 is offered isn't clear — verify during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard